Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Phase II Pilot Study of Brentuximab Vedotin, Rituximab and Dose Attenuated CHP in Elderly Patients With DLBCL

Authors not listed

Patrick Reagan · 2016

Abstract

This is a study incorporating brentuximab vedotin and dose attenuated rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) into initial therapy for elderly patients with DLBCL. Vincristine will be omitted from the standard R-CHOP regimen given the overlapping toxicities with brentuximab vedotin.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-01 MST

Cite this

APA
Anonymous. (2016). Phase II Pilot Study of Brentuximab Vedotin, Rituximab and Dose Attenuated CHP in Elderly Patients With DLBCL. <em>Patrick Reagan</em>. https://clinicaltrials.gov/study/NCT02734771
Vancouver
Anonymous. Phase II Pilot Study of Brentuximab Vedotin, Rituximab and Dose Attenuated CHP in Elderly Patients With DLBCL. Patrick Reagan. 2016.
BibTeX
@misc{anon2016PhaseI, title = {Phase II Pilot Study of Brentuximab Vedotin, Rituximab and Dose Attenuated CHP in Elderly Patients With DLBCL}, author = {Anonymous}, journal = {Patrick Reagan}, year = {2016}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings